We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vanda CEO: FDA Communication Key to Non-Preagreed Endpoints
Vanda CEO: FDA Communication Key to Non-Preagreed Endpoints
Despite not agreeing on primary endpoints with the FDA before beginning clinical trials for a new sleep disorder drug, Vanda was able to get an almost unanimous recommendation from an advisory committee earlier this month.